Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT04093960 - Escitalopram vs Escitalopram + Lactiplantibacillus plantarum PS128 & Major depressive disorder / Major Depression / Depressive episode (MDD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background

The complex mental disorder known as major depressive disorder (MDD) may be connected to the gut-microbiota-brain axis (1)

Study overview

It is a randomized, clinical phase IV treatment trial studying Escitalopram (10 mg daily) vs Escitalopram + Lactiplantibacillus plantarum PS128 ((300 mg two times daily, equivalent to 3 ×1010 CFU two times daily) in patients with Major depressive disorder / Major Depression / Depressive episode (MDD) over eight weeks

Primary outcome measures

Depression severity by t…

References (Sources)

The effects of Lactobacillus plantarum PS128 in patients with major depressive disorder: an eight-week double-blind, placebo-controlled study
Lin et al. 2024 Asian J Psychiatr 101: 104210

AI Chat

7/2/2026

Chat with our artificial intelligence:

Start chat!